Ontario Teachers Pension Plan Board Buys Shares of 43,281 Amgen, Inc. (NASDAQ:AMGN)

Ontario Teachers Pension Plan Board bought a new position in shares of Amgen, Inc. (NASDAQ:AMGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 43,281 shares of the medical research company’s stock, valued at approximately $8,426,000.

Several other hedge funds have also made changes to their positions in the company. Ruggie Capital Group boosted its stake in shares of Amgen by 297.1% during the 4th quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock worth $26,000 after acquiring an additional 101 shares during the period. Arlington Partners LLC lifted its holdings in Amgen by 86.7% during the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after purchasing an additional 65 shares during the last quarter. Massey Quick Simon & CO. LLC lifted its holdings in Amgen by 710.5% during the 4th quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock worth $30,000 after purchasing an additional 135 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in Amgen during the 4th quarter worth approximately $39,000. Finally, Prime Capital Investment Advisors LLC acquired a new stake in Amgen during the 4th quarter worth approximately $42,000. Institutional investors own 79.18% of the company’s stock.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total transaction of $377,760.00. Following the completion of the transaction, the director now directly owns 14,988 shares of the company’s stock, valued at $2,830,933.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 6,000 shares of company stock valued at $1,144,120. 0.27% of the stock is owned by corporate insiders.

Shares of Amgen stock traded down $5.00 on Friday, hitting $177.47. The company had a trading volume of 8,266,592 shares, compared to its average volume of 2,669,918. The company has a market cap of $109.31 billion, a PE ratio of 12.32, a price-to-earnings-growth ratio of 2.17 and a beta of 1.21. Amgen, Inc. has a 1 year low of $165.22 and a 1 year high of $210.19. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.26 by $0.16. The firm had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same period in the prior year, the business posted $2.89 earnings per share. As a group, research analysts anticipate that Amgen, Inc. will post 13.96 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 3.27%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is 40.28%.

Several brokerages have weighed in on AMGN. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. Goldman Sachs Group reissued a “buy” rating and set a $232.00 price target on shares of Amgen in a report on Thursday, January 17th. Oppenheimer set a $224.00 price target on Amgen and gave the stock a “buy” rating in a report on Sunday, January 27th. Royal Bank of Canada reissued a “neutral” rating and set a price target on shares of Amgen in a report on Monday, January 14th. Finally, Citigroup boosted their price objective on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a research report on Friday, January 4th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Amgen presently has a consensus rating of “Hold” and a consensus price target of $209.11.

ILLEGAL ACTIVITY WARNING: “Ontario Teachers Pension Plan Board Buys Shares of 43,281 Amgen, Inc. (NASDAQ:AMGN)” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/ontario-teachers-pension-plan-board-invests-8-43-million-in-amgen-inc-amgn-stock.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: Channel Trading

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.